Journal ArticleDOI
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon,Anne Costes,Fátima Sánchez-Cabo,Amos Kirilovsky,Bernhard Mlecnik,Christine Lagorce-Pagès,Marie Tosolini,Matthieu Camus,Anne Berger,Philippe Wind,Franck Zinzindohoué,Patrick Bruneval,Paul-Henri Cugnenc,Zlatko Trajanoski,Wolf H. Fridman,Franck Pagès +15 more
Reads0
Chats0
TLDR
In situ analysis of tumor-infiltrating immune cells may be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.Abstract:
The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.read more
Citations
More filters
Journal ArticleDOI
Optimizing oncolytic virotherapy in cancer treatment.
Kevin J. Harrington,Daniel J. Freeman,Beth Kelly,James Harper,Jean-Charles Soria,Jean-Charles Soria +5 more
TL;DR: Rational combinations of OVs with different immune modifiers and/or antitumour agents, based on mechanisms of tumour resistance to immune-mediated attack, may benefit the large, currently underserved, population of patients who respond poorly to immune checkpoint inhibition.
Journal ArticleDOI
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Maud Toulmonde,Nicolas Penel,Julien Adam,Julien Adam,Christine Chevreau,Jean-Yves Blay,Axel Le Cesne,Emmanuelle Bompas,Sophie Piperno-Neumann,Sophie Cousin,Thomas Grellety,Thomas Ryckewaert,Alban Bessede,François Ghiringhelli,Marina Pulido,Antoine Italiano +15 more
TL;DR: It is found that PD-1 inhibition has limited activity in selected STS and GIST, and may be explained by an immunosuppressive tumor microenvironment resulting from macrophage infiltration and IDO1 pathway activation.
Journal ArticleDOI
IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells
Donggou He,Hui Li,Nabiha Yusuf,Nabiha Yusuf,Craig A. Elmets,Craig A. Elmets,Jun Li,John D. Mountz,John D. Mountz,Hui Xu +9 more
TL;DR: It is demonstrated that IL-17–mediated responses promote tumor development through the induction of tumor-promoting microenvironments at tumor sites through the involvement of MDSCs in tumor sites.
Journal ArticleDOI
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat,Alejandro Navarro,Laia Paré,Noemi Reguart,Patricia Galván,Tomás Pascual,A. Martinez,Paolo Nuciforo,Laura Comerma,Llucia Alos,N. Pardo,Susana Cedres,Cheng Fan,Joel S. Parker,Lydia Gaba,Iván Victoria,Nuria Viñolas,Ana Vivancos,Ana Arance,Enriqueta Felip +19 more
TL;DR: The hypothesis that identification of a preexisting and stable adaptive immune response as defined by mRNA expression pattern is reproducible and sufficient to predict clinical outcome is supported, regardless of the type of cancer or the PD1 therapeutic antibody administered to patients.
Journal ArticleDOI
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Suzanne Mosely,John E. Prime,Richard C.A. Sainson,Jens-Oliver Koopmann,Dennis Wang,Danielle Greenawalt,Miika Ahdesmaki,Rebecca Leyland,Stefanie R. Mullins,Luciano Pacelli,Danielle Marcus,Judith Anderton,Amanda Watkins,Jane Coates Ulrichsen,Philip Brohawn,Brandon W. Higgs,Matthew McCourt,Hazel Jones,James Harper,Michelle Morrow,Viia Valge-Archer,Ross Stewart,Simon J. Dovedi,Robert W. Wilkinson +23 more
TL;DR: Characterization of murine syngeneic tumor models highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of immunotherapies as well as combinations with targeted therapies in vivo.
References
More filters
Journal ArticleDOI
Inflammation and cancer
Lisa M. Coussens,Zena Werb +1 more
TL;DR: It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration.
Journal ArticleDOI
Cancer immunoediting: from immunosurveillance to tumor escape.
TL;DR: The historical and experimental basis of cancer immunoediting is summarized and its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction are discussed.
Journal ArticleDOI
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
P. van der Bruggen,Catia Traversari,Patrick Chomez,Christophe Lurquin,E De Plaen,B Van den Eynde,Alexander Knuth,Thierry Boon +7 more
TL;DR: In this paper, a gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line, which belongs to a family of at least three genes.
Journal ArticleDOI
Tumour-educated macrophages promote tumour progression and metastasis
TL;DR: Macrophages are educated by the tumour microenvironment, so that they adopt a trophic role that facilitates angiogenesis, matrix breakdown and tumour-cell motility — all of which are elements of the metastatic process.
Related Papers (5)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J. Curiel,George Coukos,Linhua Zou,Xavier Alvarez,Pui Cheng,Peter Mottram,Melina Evdemon-Hogan,Jose R. Conejo-Garcia,Lin Zhang,Matthew E. Burow,Yun Zhu,Shuang Wei,Ilona Kryczek,Ben Daniel,Alan N. Gordon,Leann Myers,Andrew A. Lackner,Mary L. Disis,Keith L. Knutson,Lieping Chen,Weiping Zou +20 more